NewEdge Advisors’s INmune Bio INMB Stock Holding History

NewEdge Advisors’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.65K	Hold	5,000	–	–	﹤0.01%	3555
2025 Q4	$7.8K	Hold	5,000	–	–	﹤0.01%	3541
2025 Q3	$10.3K	Hold	5,000	–	–	﹤0.01%	3316
2025 Q2	$11.6K	Hold	5,000	–	–	﹤0.01%	3160
2025 Q1	$39K	Hold	5,000	–	–	﹤0.01%	2632
2024 Q4	$23.4K	Hold	5,000	–	–	﹤0.01%	2765
2024 Q3	$26.9K	Sell	5,000 -5,475	-52%	-$38.9K	﹤0.01%	2632
2024 Q2	$92.4K	Hold	10,475	–	–	﹤0.01%	2145
2024 Q1	$123K	Buy	10,475 +50	+0.5%	+$604	﹤0.01%	2005
2023 Q4	$117K	Buy	10,425 +5,000	+92%	+$41.9K	﹤0.01%	1895
2023 Q3	$36.7K	Buy	+5,425	New	+$45K	﹤0.01%	2187

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

NewEdge Advisors's INMB Position: Q1 2026 in Review

NewEdge Advisors held its INmune Bio (INMB) position steady in Q1 2026 at 5,000 shares worth $5.65K. The position accounts for ﹤0.01% of the portfolio, ranked #3555.

NewEdge Advisors first reported a position in INMB in Q3 2023 and has held it in 11 quarters since. The position peaked at $123K in Q1 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

NewEdge Advisors held 5,000 shares of INmune Bio worth $5.65K as of Q1 2026.
NewEdge Advisors left its INmune Bio share count unchanged in Q1 2026.
INmune Bio made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3555 holding.
NewEdge Advisors first reported a position in INmune Bio in Q3 2023 and has held it in 11 quarters since.
NewEdge Advisors's INmune Bio position peaked at $123K in Q1 2024.
82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.